WO2016041036A1 - Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique - Google Patents

Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique Download PDF

Info

Publication number
WO2016041036A1
WO2016041036A1 PCT/BR2015/000146 BR2015000146W WO2016041036A1 WO 2016041036 A1 WO2016041036 A1 WO 2016041036A1 BR 2015000146 W BR2015000146 W BR 2015000146W WO 2016041036 A1 WO2016041036 A1 WO 2016041036A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
antiespasmodic
analgesic
analgesic agent
pharmaceutical combination
Prior art date
Application number
PCT/BR2015/000146
Other languages
English (en)
Portuguese (pt)
Inventor
Jaime ABRAMOWICZ
Fernando Rafael De Souza
Carlos Antonio Martins
Original Assignee
Diffucap Chemobras Química E Farmacéutical Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102014023319A external-priority patent/BR102014023319A2/pt
Application filed by Diffucap Chemobras Química E Farmacéutical Ltda filed Critical Diffucap Chemobras Química E Farmacéutical Ltda
Priority to EP15842123.0A priority Critical patent/EP3195864A4/fr
Priority to RU2017111270A priority patent/RU2017111270A/ru
Priority to US15/512,110 priority patent/US20170281596A1/en
Publication of WO2016041036A1 publication Critical patent/WO2016041036A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Definitions

  • Combinations of antispasmodics and analgesics are known in the market for the treatment of gastrointestinal, biliary tract and genitouriary tract pain. These preparations combine the action of an antispasmodic with various analgesics such as Paracetamol, Dipyrone and Ibuprofen, and there is no history of a combination of an antispasmodic with Tromethamine Ketorolac as an analgesic agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique, l'agent analgésique étant le kétorolac trométhamine physiquement isolé de l'agent antispasmodique, le principe actif antispasmodique en combinaison avec l'agent analgésique kétorolac trométhamine étant l'hyoscine, la pargévérine, la toltérodine, la mébévérine ou la papavérine. L'agent analgésique kétorolac trométhamine et l'agent antispasmodique sont combinés sous une forme séparée et à libération immédiate. L'agent analgésique kétorolac trométhamine peut également se présenter, dans la présente combinaison, sous une forme séparée et à libération immédiate, l'agent antispasmodique combiné se présentant sous une forme également séparée, mais à libération programmée. Le principe actif kétorolac trométhamine est présent en proportion comprise entre 2,5% et 20% en poids et le principe actif antispasmodique est présent en proportion comprise entre 2,5% et 20% en poids.
PCT/BR2015/000146 2013-09-20 2015-09-17 Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique WO2016041036A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP15842123.0A EP3195864A4 (fr) 2013-09-20 2015-09-17 Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique
RU2017111270A RU2017111270A (ru) 2013-09-20 2015-09-17 Фармацевтическая комбинация, содержащая агент анальгетик и спазмолитический агент
US15/512,110 US20170281596A1 (en) 2013-09-20 2015-09-17 Pharmaceutical combination containing an analgesic agent and an antispasmodic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102014023319A BR102014023319A2 (pt) 2013-09-20 2014-09-19 combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico
BRBR1020140233199 2014-09-19

Publications (1)

Publication Number Publication Date
WO2016041036A1 true WO2016041036A1 (fr) 2016-03-24

Family

ID=55537066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2015/000146 WO2016041036A1 (fr) 2013-09-20 2015-09-17 Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique

Country Status (1)

Country Link
WO (1) WO2016041036A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152674A1 (fr) 2022-02-09 2023-08-17 Berlia Sushma Paul Combinaison pharmaceutique d'agent antispasmodique et anxiolytique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103389A1 (fr) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Formulation à libération retardée pour réduire la fréquence de miction et son procédé d'utilisation
WO2014075155A1 (fr) * 2012-11-14 2014-05-22 Diffucap Chemobras Química E Farmacêutica Ltda Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique
WO2015027303A1 (fr) * 2013-08-28 2015-03-05 Diffucap Chemobras Quimica E Farmaceutica Ltda Procédé de fabrication d'une combinaison pharmaceutique contenant un agent analgésique et un agent anti-spasmodique et combinaison pharmaceutique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103389A1 (fr) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Formulation à libération retardée pour réduire la fréquence de miction et son procédé d'utilisation
WO2014075155A1 (fr) * 2012-11-14 2014-05-22 Diffucap Chemobras Química E Farmacêutica Ltda Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique
WO2015027303A1 (fr) * 2013-08-28 2015-03-05 Diffucap Chemobras Quimica E Farmaceutica Ltda Procédé de fabrication d'une combinaison pharmaceutique contenant un agent analgésique et un agent anti-spasmodique et combinaison pharmaceutique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Umang Pharmaceuticals.", HYOSCINE BUTYLBROMIDE PELLETS, 20 October 2015 (2015-10-20), XP009502656, Retrieved from the Internet <URL:http://www.umangpharinaceuticals.com/pharmaceutical-pellets/hyoscine-butylbromide-pellets.php> *
DEL VALLE-LAISEQUILLA, C.F. ET AL.: "Ketorolac Tromethamine Improves the Analgesic Effect of Hyoscine Butylbromide in Patients with Intense Cramping Pain from Gastrointestinal or Genitourinary Origin.", ARZNEIMITTELFORSCHUNG, vol. 62, 2012, pages 603 - 608, XP055419153 *
DESTRO, M. ET AL.: "Physical compatibility of binary and ternary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care.", SUPPORT CARE CANCER, vol. 20, 2012, pages 2501 - 2509, XP035104900, doi:10.1007/s00520-011-1363-x *
ETMAN, M. ET AL.: "Formulation of sustained-release ketorolac tromethamine pellets.", PHARMACEUTICAL TECHNOLOGY, vol. 32, no. 12, 2008, pages 58 - 61, XP055419181 *
LÜ W.L. ET AL.: "Preparation of scopolamine hydrobromide nanoparticles-in-microsphere system.", YAO XUE XUE BAO, vol. 45, no. 7, 2010, pages 914 - 919, XP009501067 *
PEZZINI, B.R ET AL.: "Formas farmacêuticas sólidas orais de liberação prolongada: sistemas monolíticos e multiparticulados.", REVISTA BRASILEIRA DE CIÊNCIAS FARMACÊUTICAS, vol. 43, no. 4, 2007, pages 491 - 502, XP055419177 *
See also references of EP3195864A4 *
THRUSH D.N; ET AL.: "Ketorolac as a premedicant for coronary artery bypass surgery patients with normal ventricles.", NURSE ANESTH., vol. 4, no. 4, 1993, pages 155 - 159, XP009501060 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152674A1 (fr) 2022-02-09 2023-08-17 Berlia Sushma Paul Combinaison pharmaceutique d'agent antispasmodique et anxiolytique

Similar Documents

Publication Publication Date Title
US11844773B2 (en) Solid solution compositions and use in chronic inflammation
JP6389190B2 (ja) 固溶体組成物および慢性炎症における使用
US11992555B2 (en) Solid solution compositions and use in chronic inflammation
US9271950B2 (en) Compositions for treating chronic inflammation and inflammatory diseases
BR112015015870B1 (pt) Uso de uma composição farmacêutica
WO2014075155A1 (fr) Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique
WO2016041036A1 (fr) Combinaison pharmaceutique contenant un agent analgésique et un agent antispasmodique
US8835495B2 (en) Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association
BRPI0906158B1 (pt) composição farmacêutica de liberação modificada compreendendo doxofilina e processo para a preparação de composição
BR102014023319A2 (pt) combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico
BR102012029127A2 (pt) Combinação farmacêutica contendo agente analgésico e agente antiespasmódico
JP2008285475A (ja) ロキソプロフェンを含有する抗アデノウイルス剤
JP2004035535A (ja) 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法
BR102013028912A2 (pt) composição farmacêutica, forma farmacêutica oral, cápsula, comprimido de dupla camada, usos, método de tratamento de hipercolesterolemia, hipertrigliceridemia e/ou dislipidemia mista e método de prevenção de aterosclerose, diabetes ou prevenção secundária de outras doenças cardiovasculares
WO2015027303A1 (fr) Procédé de fabrication d&#39;une combinaison pharmaceutique contenant un agent analgésique et un agent anti-spasmodique et combinaison pharmaceutique
JP2501201B2 (ja) 感冒薬
BR102013021950B1 (pt) procedimento de fabricação de combinação farmacêutica contendo agente analgésico e agente antiespasmódico e combinação farmacêutica
WO2024171075A1 (fr) Compositions comprenant de l&#39;ibogaïne, éventuellement en combinaison avec des n-acyléthanolamines, et leurs utilisations
JP6067339B2 (ja) 安全な解熱剤組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15842123

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15512110

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015842123

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015842123

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017111270

Country of ref document: RU

Kind code of ref document: A